Lacosamide Viatris

Lacosamide, the active ingredient in Lacosamide Viatris, is an anticonvulsant presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces the frequency and severity of focal seizures. - Epilepsy (adjunct therapy): helps achieve better overall seizure control when added to existing regimens. - Refractory focal epilepsy: provides an additional option for patients whose seizures are not controlled by first‑line agents.

Lacosamide may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Headache: mild to moderate pain in the head. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing conditions. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe hypersensitivity: anaphylaxis or angioedema. - Rhabdomyolysis: muscle breakdown leading to kidney injury. - Life‑threatening skin reactions: toxic epidermal necrolysis.

Before prescribing Lacosamide, clinicians should consider several safety measures. - Cardiac monitoring: assess ECG for PR‑interval prolongation in patients with cardiac disease. - Renal function: adjust use in patients with impaired renal clearance. - Hepatic impairment: evaluate liver function and consider dose adjustment. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Abrupt discontinuation: taper gradually to avoid seizure exacerbation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): additive risk of cardiac conduction effects. - QT‑prolonging agents (e.g., amiodarone): heightened risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Alcohol and CNS depressants: may enhance sedation and dizziness. - Antacids: can modestly affect absorption; monitor therapeutic response.